Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and SBRT for Pancreatic Adenocarcinoma
NCT02153450Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in pancreatic adenocarcinoma (PDAC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Dose-limiting toxicity rate at 21 days. Started May 2015; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02153450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153450.